Glyceryl Trinitrate Pfizer Healthcare Ireland

Glyceryl Trinitrate Pfizer Healthcare Ireland is an intravenous solution containing the active ingredient glyceryl trinitrate. It is a prescription‑only organic nitrate marketed in the European Union and supplied by Pfizer Healthcare Ireland. The product is formulated for intravenous administration and is classified as an anti‑anginal agent that works by releasing nitric oxide to dilate coronary and systemic vessels. It is used under medical supervision for rapid relief of cardiovascular emergencies.

Glyceryl trinitrate intravenous solution is indicated for several acute cardiovascular conditions where rapid vasodilation is required.

- Acute angina pectoris that requires rapid symptom relief when oral nitrates are ineffective. - Acute decompensated heart failure where reduction of preload and afterload can improve cardiac output. - Hypertensive emergencies, especially in patients with coronary artery disease, to achieve prompt blood pressure control. - Induction of controlled hypotension during operative or diagnostic procedures to reduce bleeding risk. - Adjunct therapy for myocardial ischemia during cardiac catheterisation or angioplasty to limit ischemic injury.

Side‑effect profile of intravenous glyceryl trinitrate reflects its potent vasodilatory action; patients may experience both frequent, generally mild reactions and rarer, potentially serious events that require clinical attention.

Common: - Headache, often described as throbbing, due to cerebral vasodilation. - Flushing or a sensation of warmth, typically affecting the face and neck. - Transient hypotension accompanied by dizziness or light‑headedness, especially after rapid infusion.

Serious: - Marked hypotension leading to syncope or loss of consciousness, requiring immediate intervention. - Myocardial ischemia caused by coronary steal, which may present as chest discomfort despite vasodilation. - Allergic reactions ranging from skin rash to anaphylaxis, necessitating prompt medical management.

When using intravenous glyceryl trinitrate, clinicians should observe several precautions to minimise risk and ensure therapeutic effectiveness.

- Assess baseline blood pressure; avoid use in patients with severe hypotension (systolic <90 mmHg). - Monitor heart rate and rhythm continuously, as reflex tachycardia may occur. - Use cautiously in patients with recent myocardial infarction or unstable coronary artery disease. - Adjust dose or discontinue if signs of methemoglobinemia develop. - Avoid abrupt discontinuation after prolonged infusion to prevent rebound hypertension. - Consider pregnancy status; safety data are limited, so use only if benefit outweighs potential risk. - Ensure proper intravenous line patency to prevent extravasation and local tissue injury.

Intravenous glyceryl trinitrate may interact with several drug classes; awareness of these interactions helps maintain hemodynamic stability.

Avoid: - Other potent vasodilators (e.g., hydralazine, other nitrates) that can cause additive hypotension. - Phosphodiesterase‑5 inhibitors (sildenafil, tadalafil) which markedly increase the risk of severe hypotension.

Use with caution: - Beta‑blockers, which may blunt reflex tachycardia and affect blood pressure control. - Calcium channel blockers, especially dihydropyridines, that can enhance vasodilatory effects. - Diuretics, which may predispose to volume depletion and hypotension. - Antihypertensive agents such as ACE inhibitors or ARBs, requiring close blood pressure monitoring. - Inhaled nitric oxide therapy, which may potentiate the vasodilatory response.